InvestorsHub Logo
Followers 0
Posts 178
Boards Moderated 0
Alias Born 12/04/2013

Re: Awesomeone post# 5647

Wednesday, 07/17/2019 3:21:31 AM

Wednesday, July 17, 2019 3:21:31 AM

Post# of 9121
Of course the doctors and hospitals are the problem. They make very little money from the SC version compared to the IV version. We know from disappointing US sales of SC Rituxan that doctors are ‘comfortable’ with the IV version and are refusing to switch patients to the SC version like they do in the EU. That’s a disgrace but Roche don’t seem to be that bothered. They win either way - it’s only the patients who suffer unnecessarily. JNJ don’t seem to have considered this potential problem.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent HALO News